Table 4. Toxicity of induction and... | American Society of Hematology

Table 4.

Toxicity of induction and consolidation treatments

Toxicity	WHO grade	Patients with adverse events (%)
		Induction		Consolidation
		MOPP/ABV	ABVPP	Chemotherapy	RTx
Patients assessable		208/238^4-150	210/246^4-150	150/183^4-150	177
Neutropenia	3-4	54	42	33	15^4-151
Thrombocytopenia	3-4	9	3	7	22
Anemia	3-4	11	2	4	3
Infection	1-2	22	21	10	9
	3-4	10	7	2	1
Nausea/vomiting	3-4	9	7	3	11
Peripheral neuropathy	1-2	24	11	10	—
	3	2	1	—	—
Alopecia	3-4	18	14	—	—

Toxicity	WHO grade	Patients with adverse events (%)
		Induction		Consolidation
		MOPP/ABV	ABVPP	Chemotherapy	RTx
Patients assessable		208/238^4-150	210/246^4-150	150/183^4-150	177
Neutropenia	3-4	54	42	33	15^4-151
Thrombocytopenia	3-4	9	3	7	22
Anemia	3-4	11	2	4	3
Infection	1-2	22	21	10	9
	3-4	10	7	2	1
Nausea/vomiting	3-4	9	7	3	11
Peripheral neuropathy	1-2	24	11	10	—
	3	2	1	—	—
Alopecia	3-4	18	14	—	—

Number of patients assessable for hematologic/nonhematologic toxicity.

Percentage of leukopenic patients is given for RTx consolidation.